Eppendorf Signs Agreement for New Production Site in Penang, Malaysia

* Agreement marks the start of Eppendorf’s planned manufacturing facility in Penang
* Eppendorf will invest EUR 40 million in the site, with production expected to start in 2028
* New facility will produce selected products of the Centrifuges & Instruments portfolio for global laboratory markets
 
Penang, Malaysia, July 29, 2026 - Eppendorf has signed an agreement for a new production site in Penang, Malaysia, marking the start of its planned greenfield manufacturing facility in Bandar Cassia Technology Park. The company is investing EUR 40 million in the site, with production of initial products expected to begin in 2028.

(From left to right) Dato’ Seri Loo Lee Lian, CEO of InvestPenang, Dr. Christine Munz, CEO Eppendorf Group, The Right Honourable Mr Chow Kon Yeow, Chief Minister of Penang, and Dato' Abdul Latiff Abdul Aziz, CEO of Penang Development Corporation (PDC).

 
“Today’s signing marks a significant next step for the Eppendorf Group,” said Dr. Christine Munz, CEO of the Eppendorf Group. “For more than 30 years, Malaysia has been an important part of Eppendorf’s history in the Asia-Pacific region. With the planned new production site in Penang, we are strategically expanding our global manufacturing network and creating a high-performance production platform in Southeast Asia that will sustainably support Eppendorf’s long-term growth.”

The new facility will manufacture selected products from Eppendorf’s Centrifuges & Instruments portfolio. Eppendorf expects the site to employ around 130 people by the end of 2029.
 
About the Eppendorf Group
Eppendorf is a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world.

The product portfolio of the business units Liquid Handling, Consumables, Automated Liquid Handling, Separation & Instrumentation and Bioprocess includes, for example pipettes, pipette tips, centrifuges, mixers, ultra-freezers and bioreactors for cell and gene research. In addition, Eppendorf offers a wide range of high-quality consumables. In fiscal year 2025, the Eppendorf Group recorded consolidated revenue of €924 million and invested €60.9 million in research and development (R&D).

Eppendorf products are used in academic or industrial research laboratories, such as pharmaceutical, biotech, chemical, and food industries, as well as clinical, environmental, forensic, and industrial laboratories for process analysis, production, and quality assurance.

Since 1945, the Eppendorf Group has been headquartered in Hamburg, Germany, and today operates production and R&D sites in Europe, Asia and North America and has subsidiaries in 30 countries. The Group employs more than 4,000 people worldwide. They all act in accordance with the purpose of the company's founders: to improve human living conditions.